Omicron infections have a lower risk of long COVID than earlier variants, according to a study analyzing data from 11,000 participants.
The risk of developing long COVID is significantly lower following an infection with the Omicron variant than after an infection with earlier coronavirus variants. This was the finding of a study by University Medicine Halle, which was published in the International Journal of Infectious Diseases.
The analysis looked at information gathered from 11,000 people about their infection history, vaccination status, and post-infection symptoms. The data provide strong evidence that the risk for long-term effects after a re-infection with the coronavirus is lower if the patient did not develop long COVID after the initial infection.
Understanding Long COVID and its Relation to Variants
Long-term symptoms can develop after a coronavirus infection. This is commonly referred to as “long COVID” or “Post COVID-19 condition.” The underlying risk factors are currently under intensive investigation.
“We wanted to understand the connection between long COVID and different coronavirus variants, vaccinations, and past infections,” explains Sophie Diexer, first author of the new study and researcher at the Institute of Medical Epidemiology, Biometry and Informatics at University Medicine Halle. “Our study shows that the percentage of people who develop long COVID symptoms after an infection was lowest at the time when Omicron was prevalent.”
The risk was found to be around three to four times lower after an Omicron infection than after an infection with the wild-type variant. Around half of all wild-type infected individuals reported persisting symptoms. It should be noted, however, that the majority of all infections occurred while Omicron was dominant. “In purely numerical terms, this means that most people developed long COVID following an Omicron infection,” says Diexer.
Recovery and Reduced Risk
The study also provides strong evidence of a protective effect once the patient has recovered from a coronavirus infection. “People who did not develop persistent symptoms after their initial infection had a significantly lower risk of developing long COVID following re-infection than people who were infected with the coronavirus for the first time. We were surprised by the scale of this effect,” explains the researcher.
However, the scientists were unable to demonstrate that, in the event of a vaccine breakthrough, the vaccine had any protective effect against long COVID. Due to the timing of the study, however, it was not possible to analyze the vaccine that specifically targeted the Omicron variant.
Details and Background of the Study
The study is based on the Germany-wide DigiHero project, which more than 48,000 people participated in until June 2022. “Studies have already looked at the relationship between the risk of long COVID and the different variants, but none has taken into account infection history,” explains Professor Rafael Mikolajczyk, director of the Institute of Medical Epidemiology, Biometry and Informatics at University Medicine Halle.
“Of the respondents, approximately 11,000 reported at least one coronavirus infection that had occurred in the twelve weeks prior to when the data was collected for our study. Classification was based on the predominant variant at the time of the reported infection.”
Participants were questioned about 24 typical long COVID symptoms, with 2,822 individuals reporting that they had experienced such symptoms. Of these, 406 (14 percent) reported experiencing severe fatigue, 237 (8 percent ) severe headaches, and 202 (7 percent) severe shortness of breath. The intensity of the symptoms was not related to the coronavirus variant.
Future Investigations and DigiHero Project
Follow-up surveys are currently being conducted to explore the persistence of long COVID symptoms. “In addition to possible long-term symptoms following a coronavirus infection, DigiHero is addressing a wide range of health issues and other impacts of the COVID-19 pandemic,” adds Mikolajczyk.
On the basis of DigiHero, University Medicine Halle has also launched the Long COVID Registry in cooperation with Otto von Guericke University Magdeburg and the Rechts der Isar Hospital of the TUM School of Medicine. The registry records, for example, long COVID symptoms as well as their progression, severity, and alleviation through specific therapies.
Reference: “Association between Virus Variants, Vaccination, Previous Infections, and Post COVID-19 Risk” by Sophie Diexer, Bianca Klee, Cornelia Gottschick, Chao Xu, Anja Broda, Oliver Purschke, Mascha Binder, Thomas Frese, Matthias Girndt, Jessica I. Hoell, Irene Moor, Michael Gekle and Rafael Mikolajczyk, 25 August 2023, International Journal of Infectious Diseases.
DOI: 10.1016/j.ijid.2023.08.019
DigiHero is a Germany-wide, population-based digital health research study. To date, over 90,000 people from 14 German states have registered. Participants are invited to complete online surveys that explore issues surrounding the development of chronic disease, healthy aging, health behaviors, and the coronavirus. Five clinics and four institutes from University Medicine Halle are taking part. Other project partners include Jena University Hospital, the Leibniz Institute for Prevention Research and Epidemiology – BIPS, and the University of Bremen.

News
Repurposed drugs could calm the immune system’s response to nanomedicine
An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often used in cancer and vaccine treatments, [...]
Nano-Enhanced Hydrogel Strategies for Cartilage Repair
A recent article in Engineering describes the development of a protein-based nanocomposite hydrogel designed to deliver two therapeutic agents—dexamethasone (Dex) and kartogenin (KGN)—to support cartilage repair. The hydrogel is engineered to modulate immune responses and promote [...]
New Cancer Drug Blocks Tumors Without Debilitating Side Effects
A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI. A new cancer drug candidate, developed through a collaboration between Lawrence Livermore National Laboratory (LLNL), BridgeBio Oncology [...]
Scientists Are Pretty Close to Replicating the First Thing That Ever Lived
For 400 million years, a leading hypothesis claims, Earth was an “RNA World,” meaning that life must’ve first replicated from RNA before the arrival of proteins and DNA. Unfortunately, scientists have failed to find [...]
Why ‘Peniaphobia’ Is Exploding Among Young People (And Why We Should Be Concerned)
An insidious illness is taking hold among a growing proportion of young people. Little known to the general public, peniaphobia—the fear of becoming poor—is gaining ground among teens and young adults. Discover the causes [...]
Team finds flawed data in recent study relevant to coronavirus antiviral development
The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid this effort, researchers quickly homed in on part of SARS-CoV-2's molecular structure known as the NiRAN domain—an [...]
Drug-Coated Neural Implants Reduce Immune Rejection
Summary: A new study shows that coating neural prosthetic implants with the anti-inflammatory drug dexamethasone helps reduce the body’s immune response and scar tissue formation. This strategy enhances the long-term performance and stability of electrodes [...]
Scientists discover cancer-fighting bacteria that ‘soak up’ forever chemicals in the body
A family of healthy bacteria may help 'soak up' toxic forever chemicals in the body, warding off their cancerous effects. Forever chemicals, also known as PFAS (per- and polyfluoroalkyl substances), are toxic chemicals that [...]
Johns Hopkins Researchers Uncover a New Way To Kill Cancer Cells
A new study reveals that blocking ribosomal RNA production rewires cancer cell behavior and could help treat genetically unstable tumors. Researchers at the Johns Hopkins Kimmel Cancer Center and the Department of Radiation Oncology and Molecular [...]
AI matches doctors in mapping lung tumors for radiation therapy
In radiation therapy, precision can save lives. Oncologists must carefully map the size and location of a tumor before delivering high-dose radiation to destroy cancer cells while sparing healthy tissue. But this process, called [...]
Scientists Finally “See” Key Protein That Controls Inflammation
Researchers used advanced microscopy to uncover important protein structures. For the first time, two important protein structures in the human body are being visualized, thanks in part to cutting-edge technology at the University of [...]
AI tool detects 9 types of dementia from a single brain scan
Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan—a transformative [...]
Is plastic packaging putting more than just food on your plate?
New research reveals that common food packaging and utensils can shed microscopic plastics into our food, prompting urgent calls for stricter testing and updated regulations to protect public health. Beyond microplastics: The analysis intentionally [...]
Aging Spreads Through the Bloodstream
Summary: New research reveals that aging isn’t just a local cellular process—it can spread throughout the body via the bloodstream. A redox-sensitive protein called ReHMGB1, secreted by senescent cells, was found to trigger aging features [...]
AI and nanomedicine find rare biomarkers for prostrate cancer and atherosclerosis
Imagine a stadium packed with 75,000 fans, all wearing green and white jerseys—except one person in a solid green shirt. Finding that person would be tough. That's how hard it is for scientists to [...]
Are Pesticides Breeding the Next Pandemic? Experts Warn of Fungal Superbugs
Fungicides used in agriculture have been linked to an increase in resistance to antifungal drugs in both humans and animals. Fungal infections are on the rise, and two UC Davis infectious disease experts, Dr. George Thompson [...]